--- title: "Greensignal Bio Pharma (1275414) Financials & Shareholding" symbol: "1275414" company: "Greensignal Bio Pharma Ltd" canonical: "https://tapetide.com/stocks/1275414" generated_at: "2026-11-05T01:52:15.377Z" --- # Greensignal Bio Pharma (1275414) Canonical page: https://tapetide.com/stocks/1275414 ## Company - **In the F&O segment:** No ## Key Insights ### Strengths - Debtor days have improved from 204 to 23.6 days. ### Weaknesses - Company has low interest coverage ratio. ## Growth Rate Growth computed from the financial statements below. A window with no rate gives the reason instead of a figure. | Metric | Window | Growth | What it compares | | --- | --- | ---: | --- | | Revenue | 5Y | 13.97% | compounded annual rate, Mar 2020 to Mar 2025 | | Revenue | 3Y | 24.36% | compounded annual rate, Mar 2022 to Mar 2025 | | Revenue | 1Y | 0% | fiscal year to Mar 2025 vs the year to Mar 2024 | | Net profit | 5Y | Loss widened | compounded annual rate, Mar 2020 to Mar 2025: -₹4.00 Cr to -₹32.00 Cr. A loss at both ends, larger at the end. | | Net profit | 3Y | Loss widened | compounded annual rate, Mar 2022 to Mar 2025: -₹15.00 Cr to -₹32.00 Cr. A loss at both ends, larger at the end. | | Net profit | 1Y | Loss narrowed | fiscal year to Mar 2025 vs the year to Mar 2024: -₹36.00 Cr to -₹32.00 Cr. A loss at the start, and a smaller one or none at the end. | | Operating cash flow | 5Y | Outflow narrowed | compounded annual rate, Mar 2020 to Mar 2025: -₹11.00 Cr to -₹1.00 Cr. A cash outflow at the start, and a smaller one or none at the end. | | Operating cash flow | 3Y | Outflow narrowed | compounded annual rate, Mar 2022 to Mar 2025: -₹26.00 Cr to -₹1.00 Cr. A cash outflow at the start, and a smaller one or none at the end. | | Operating cash flow | 1Y | Outflow narrowed | fiscal year to Mar 2025 vs the year to Mar 2024: -₹123 Cr to -₹1.00 Cr. A cash outflow at the start, and a smaller one or none at the end. | | Operating margin | 5Y | -68.92 pp | compounded annual rate, Mar 2020 to Mar 2025 | | Operating margin | 3Y | -53.54 pp | compounded annual rate, Mar 2022 to Mar 2025 | | Operating margin | 1Y | -12.00 pp | fiscal year to Mar 2025 vs the year to Mar 2024 | Trailing twelve months: No quarterly results are reported. ## Financial Statements ### Profit & Loss Figures in ₹ crore unless the row name gives another unit. | Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Sales | 27 | 30 | 29 | 13 | 28 | 13 | 25 | 25 | | Expenses | 19 | 23 | 15 | 16 | 19 | 18 | 45 | 48 | | Operating Profit | 8 | 7 | 14 | -3 | 9 | -5 | -20 | -23 | | OPM % | 31% | 23% | 49% | -22% | 31% | -37% | -78% | -90% | | Other Income | 0 | 0 | 2 | 2 | 0 | -4 | 0 | 1 | | Interest | 1 | 0 | 0 | 0 | 0 | 0 | 7 | 1 | | Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 8 | 8 | | Profit before tax | 6 | 4 | 13 | -4 | 6 | -13 | -34 | -31 | | Tax % | 37% | 29% | 24% | 2% | 16% | 19% | 6% | 4% | | Net Profit | 4 | 3 | 10 | -4 | 5 | -15 | -36 | -32 | | EPS in Rs | 0.93 | 0.76 | 2.59 | -1.12 | 1.4 | -3.96 | -9.37 | -8.37 | | Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ### Balance Sheet Figures in ₹ crore unless the row name gives another unit. | Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 38 | | Reserves | 11 | 13 | 23 | 18 | 24 | 9 | -57 | -89 | | Borrowings | 3 | 0 | 0 | 0 | 48 | 108 | 256 | 341 | | Other Liabilities | 6 | 7 | 7 | 7 | 9 | 9 | 39 | 29 | | Total Liabilities | 58 | 58 | 68 | 63 | 119 | 164 | 276 | 319 | | Fixed Assets | 39 | 35 | 33 | 31 | 28 | 58 | 117 | 121 | | CWIP | 0 | 0 | 0 | 0 | 45 | 45 | 46 | 102 | | Investments | 0 | 8 | 12 | 0 | 0 | 2 | 0 | 1 | | Other Assets | 19 | 16 | 22 | 32 | 46 | 59 | 113 | 95 | | Total Assets | 58 | 58 | 68 | 63 | 119 | 164 | 276 | 319 | ### Cash Flow Figures in ₹ crore unless the row name gives another unit. | Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash from Operating Activity | -1 | 12 | 4 | -11 | -2 | -26 | -123 | -1 | | Cash from Investing Activity | -3 | 1 | -2 | 0 | -42 | -34 | -21 | -65 | | Cash from Financing Activity | 0 | 3 | -5 | 12 | 48 | 59 | 142 | 74 | | Net Cash Flow | -4 | 16 | -2 | 1 | 5 | 0 | -2 | 7 | | Free Cash Flow | -4 | 14 | 3 | -11 | -2 | -59 | -141 | -13 | | CFO/OP | 13 | 189 | 31 | 375 | -18 | 532 | 630 | 6 | ### Ratios | Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Debtor Days | 64 | 34 | 85 | 129 | 92 | 1 | 384 | 24 | | Inventory Days | 548 | 113 | 551 | 404 | 255 | 259 | 356 | 382 | | Days Payable | 97 | 63 | 69 | 50 | 81 | 79 | 674 | 357 | | Cash Conversion Cycle | 515 | 85 | 567 | 482 | 267 | 180 | 65 | 48 | | Working Capital Days | 151 | 75 | 188 | 668 | 455 | 1,384 | 1,156 | 826 | | ROCE % | — | 9% | 24% | -7% | 8% | -6% | — | -11% | ## Frequently Asked Questions about Greensignal Bio Pharma ### What does Greensignal Bio Pharma Ltd do? Greensignal Bio Pharma Limited was incorporated on 21st November 2005 as a Private Limited Company. The Company changed its name to GreenSignal Bio Pharma Private Limited on 21st April 2016. ## Company Information Greensignal Bio Pharma Limited was incorporated on 21st November 2005 as a Private Limited Company. The Company changed its name to GreenSignal Bio Pharma Private Limited on 21st April 2016. The Company has been converted into Public Limited Company consequent to issue of revised Certificate of Incorporation dated 12th May 2016 by the Registrar of Companies. The Company has been converted into Private Limited Company consequent to issue of revised Certificate of Incorporation dated 29th December 2017 by the Registrar of Companies. The Company produces Life Saving Vaccine, namely, BCG Vaccine. - **Face Value:** ₹10 --- Negative figures use an ASCII hyphen-minus (-) so they parse as numbers. Amounts are in Indian rupees; "Cr" is crore (10 million). Dates are Indian Standard Time. Financial statements, shareholding and filings are as reported by the company. Price, volume and 52-week levels are market data. Technical indicators are computed by Tapetide from daily prices. The Tapetide Score is Tapetide’s own analysis. Analyst ratings and forecasts are the published estimates of third-party analysts, not company statements. The AI sections are generated text. For research and information only, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser. Generated 5 Nov 2026, 07:22 IST.